shape-element-one
shape-element-two
Oncology
Back To Full Menu

TumorNext-Lynch

When you need to rule out or confirm Lynch syndrome or to determine if your patient can start PD-LI or PD-1 immunotherapy you need a test that gives you the most comprehensive and accurate information. TumorNext-Lynch is a single test that looks at both tumor and germline mutations, giving you clearer information to better guide treatment decisions.
Lynch Syndrome Genetic Testing | TumorNext-Lynch

When you need to rule out or confirm Lynch syndrome or to determine if your patient can start PD-LI or PD-1 immunotherapy you need a test that gives you the most comprehensive and accurate information. TumorNext-Lynch is a single test that looks at both tumor and germline mutations, giving you clearer information to better guide treatment decisions.

  • Tumor and germline paired analysis of MLH1, MSH2, MSH6, PMS2, and EPCAM
  • Microsatellite instability (MSI)
  • MLH1 promoter hypermethylation analysis.
  • Option to add on BRAF (V600E), NRAS, and KRAS targeted analysis
  • The following tumor types will be accepted (assuming all other specimen requirements are met): colorectal, endometrial, ovarian, Fallopian tube, primary peritoneal, small bowel, stomach, pancreas, appendiceal, gallbladder, bladder, ureter, renal pelvis, sebaceous cancer, prostate, and colorectal polyps with high grade dysplasia. For more details, please refer to the Tumor Specimen Requirements. 
Genes analyzed
Product Summary
Private: TumorNext-Lynch
(EN)
Case Example
Private: TumorNext-Lynch
(EN)

Get more complete information to guide healthcare decisions with one test to rule out or confirm Lynch syndrome Know if your patient is at an increased risk for other cancers, so you can modify screening and prevention recommendations  Guide treatment decisions based on BRAF/KRAS/NRAS mutation status Guide treatment options for PD-L1/PD-1 immunotherapy based on MMR deficiency status